Syngene International to invest $100 million in Mangalore
Advertisement
Syngene International is planning to make an investment of $100 million in Mangalore to set up a manufacturing plant
The contract research arm of biotechnology major Biocon, Syngene International is setting up a manufacturing plant in Mangalore with an investment of about $ 100 million. The process is reported to have been initiated by the company to acquire 40 acres of land.
"The company is planning to set up a new manufacturing facility at Mangalore SEZ and is in the process of acquiring 40 acres of land and obtaining necessary approvals," Syngene International said in a statement on BSE.
The estimated expenditure for setting up the facility is $100 million, it added.
"We will intimate the exchanges with appropriate details in the first half of 2016 after completing the detailed engineering for the proposed project," the company said.
Incorporated in 1993, Syngene offers discovery and development services for novel molecular entities (NMEs) across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition, as reported by PTI.
The contract research arm of biotechnology major Biocon, Syngene International is setting up a manufacturing plant in Mangalore with an investment of about $ 100 million. The process is reported to have been initiated by the company to acquire 40 acres of land.
"The company is planning to set up a new manufacturing facility at Mangalore SEZ and is in the process of acquiring 40 acres of land and obtaining necessary approvals," Syngene International said in a statement on BSE.
The estimated expenditure for setting up the facility is $100 million, it added.
"We will intimate the exchanges with appropriate details in the first half of 2016 after completing the detailed engineering for the proposed project," the company said.
Incorporated in 1993, Syngene offers discovery and development services for novel molecular entities (NMEs) across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition, as reported by PTI.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.